ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 289,31
0,43%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioCardia Inc (BCDA)

  7. BioCardia Inc (BCDA) Actualités

BCDA

BioCardia (BCDA)

BioCardia Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BCDA
DateHeureSourceTitreSymboleSociété
07/06/202413h00GlobeNewswire Inc.BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery ApproachNASDAQ:BCDABioCardia Inc
21/05/202423h00GlobeNewswire Inc.BioCardia Announces Reverse Stock SplitNASDAQ:BCDABioCardia Inc
14/05/202422h02GlobeNewswire Inc.BioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
01/05/202413h00GlobeNewswire Inc.BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesNASDAQ:BCDABioCardia Inc
25/04/202415h00GlobeNewswire Inc.BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortNASDAQ:BCDABioCardia Inc
27/03/202421h00GlobeNewswire Inc.BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
20/03/202412h00GlobeNewswire Inc.BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024NASDAQ:BCDABioCardia Inc
13/03/202412h00GlobeNewswire Inc.BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipNASDAQ:BCDABioCardia Inc
12/03/202412h00GlobeNewswire Inc.BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyNASDAQ:BCDABioCardia Inc
04/03/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCDABioCardia Inc
04/03/202414h00GlobeNewswire Inc.BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureNASDAQ:BCDABioCardia Inc
27/02/202422h53Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BCDABioCardia Inc
15/02/202413h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCDABioCardia Inc
14/02/202423h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCDABioCardia Inc
14/02/202422h17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BCDABioCardia Inc
08/02/202413h00GlobeNewswire Inc.BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDANASDAQ:BCDABioCardia Inc
31/01/202413h00GlobeNewswire Inc.BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics ConferenceNASDAQ:BCDABioCardia Inc
03/01/202413h00GlobeNewswire Inc.BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for ShareholdersNASDAQ:BCDABioCardia Inc
19/12/202313h00GlobeNewswire Inc.BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionNASDAQ:BCDABioCardia Inc
18/12/202313h16GlobeNewswire Inc.BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesNASDAQ:BCDABioCardia Inc
06/12/202312h03Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCDABioCardia Inc
06/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BCDABioCardia Inc
05/12/202322h11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:BCDABioCardia Inc
29/11/202313h00GlobeNewswire Inc.BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalNASDAQ:BCDABioCardia Inc
16/11/202318h56GlobeNewswire Inc.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesNASDAQ:BCDABioCardia Inc
14/11/202313h15GlobeNewswire Inc.BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart FailureNASDAQ:BCDABioCardia Inc
08/11/202322h11GlobeNewswire Inc.BioCardia Reports Third Quarter 2023 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
08/11/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCDABioCardia Inc
01/11/202322h04GlobeNewswire Inc.BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023NASDAQ:BCDABioCardia Inc
19/10/202323h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BCDABioCardia Inc
 Showing the most relevant articles for your search:NASDAQ:BCDA

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
NASDAQ
NVDA
NVIDIA
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
PX4
SBF 120
EU
HO
Thales
EU
PX1
CAC 40
EU
BEL20
Bel 20
EU
VK
Vallourec
EU
RI
Pernod Ricard
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
NYSE
DIS
Walt Disney
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés